J Biomed 2017; 2:94-100. doi:10.7150/jbm.19834 This volume
Melanoma from Molecular Pathways to Clinical Treatment: An Up to Date Review
1. 3rd Surgical Department, "AHEPA" University General Hospital, Aristotle University of Thessaloniki;
2. Oncology Department, Interbalkan European Medical Center;
3. Surgery Department, Interbalkan European Medical Center;
4. Pulmonary Department-Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;
5. Laboratory of Proteomics and Protein Sciences, Veterans Affair Health System, Baltimore, MD, USA.
Kosmidis C, Baka S, Sapalidis K, Mixalopoulos N, Atmatzidis S, Koulouris H, Anthimidis G, Varsamis N, Zarogoulidis P, Man YG, Georgakoudi E, Mantalovas S, Koimtzis G, Tsakalidis A, Kesisoglou I. Melanoma from Molecular Pathways to Clinical Treatment: An Up to Date Review. J Biomed 2017; 2:94-100. doi:10.7150/jbm.19834. Available from /v02p0094.htm
Skin cancer is divided to melanoma and non-melanoma. Melanoma occurs due to deregulation of melanocytes. Melanoma is frequent in Caucasian population. During the last decade there is an increase in melanoma and in many cases there is a diagnostic challenge. Moreover; choosing the right treatment is a challenge for many patients. Malignant melanoma is known to be a lethal disease due to its aggressive capacity for metastasis and resistance to therapy. In the last decade, considerable efforts have gone into development of an effective immunotherapy for treatment of melanoma. The combination of macrophage activation and other treatments such as immunotherapy, surgery, chemotherapy, and radiotherapy, may provide an effective and comprehensive anti-melanoma strategy.
Keywords: Melanoma, immunotherapy, molecular pathways.